Private Wealth Asset Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 210.7% during the third quarter, Holdings Channel reports. The institutional investor owned 66,645 shares of the company’s stock after purchasing an additional 45,195 shares during the period. Johnson & Johnson comprises about 1.0% of Private Wealth Asset Management LLC’s portfolio, making the stock its 18th largest holding. Private Wealth Asset Management LLC’s holdings in Johnson & Johnson were worth $18,409,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Alteri Wealth LLC raised its stake in shares of Johnson & Johnson by 3.4% in the third quarter. Alteri Wealth LLC now owns 8,604 shares of the company’s stock worth $2,278,000 after purchasing an additional 286 shares during the last quarter. Greenline Wealth Management LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $212,000. Private Advisor Group LLC lifted its holdings in shares of Johnson & Johnson by 34.6% in the third quarter. Private Advisor Group LLC now owns 373,648 shares of the company’s stock valued at $98,920,000 after purchasing an additional 95,960 shares in the last quarter. Tyche Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 41.2% during the third quarter. Tyche Wealth Partners LLC now owns 31,618 shares of the company’s stock valued at $8,371,000 after buying an additional 9,219 shares during the last quarter. Finally, Taylor Hoffman Capital Management LLC boosted its position in shares of Johnson & Johnson by 0.4% during the third quarter. Taylor Hoffman Capital Management LLC now owns 31,107 shares of the company’s stock valued at $8,235,000 after buying an additional 135 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.
Johnson & Johnson News Summary
These are some of the JNJ news items that stood out recently:
- Positive Sentiment: Memorial Hermann-Texas Medical Center will be the first hospital to install the OTTAVA robotic surgical system as part of an early-access commercial launch. This marks a step toward monetizing the platform following its FDA De Novo authorization. Article
- Positive Sentiment: Johnson & Johnson filed for FDA approval to expand CAPLYTA to bipolar I mania or mixed episodes. Two Phase 3 studies showed symptom improvement versus placebo; approval would add a potential fifth adult indication, but remains uncertain. Article
- Negative Sentiment: Healthcare stocks were broadly weaker during Thursday afternoon trading, a sector headwind that may have contributed to pressure on JNJ alongside company-specific news. Sector update
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $267.02 on Friday. The stock has a fifty day simple moving average of $267.43 and a two-hundred day simple moving average of $250.79. Johnson & Johnson has a 1-year low of $199.90 and a 1-year high of $290.25. The firm has a market cap of $642.80 billion, a price-to-earnings ratio of 40.46, a price-to-earnings-growth ratio of 2.74 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the company. Morgan Stanley decreased their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a report on Thursday, October 15th. Wells Fargo & Company raised their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Royal Bank Of Canada cut their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research note on Monday, August 3rd. Finally, Citigroup increased their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $275.92.
Check Out Our Latest Report on Johnson & Johnson
Insider Activity at Johnson & Johnson
In related news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,832,923.66. The trade was a 43.48% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
See Also
- Five stocks we like better than Johnson & Johnson
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
